Huber Martin H. Jr.
- SEC CIK
- 0001653276
No open-market purchases or sales filed in the past year.
Current role at each company
- ACTU Actuate Therapeutics, Inc.Directoras of May 22, 2026
- SNDX Syndax Pharmaceuticals IncDirectoras of Feb 6, 2026
- MRSN Mersana Therapeutics, Inc.President, CEOas of Jan 6, 2026
- XLO Xilio Therapeutics, Inc.PRESIDENT AND HEAD OF R&Das of Aug 18, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Huber Martin H. Jr. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MRSN Mersana Therapeutics, Inc.
President, CEO3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2025 (view filing) | Sep 12 | 3 days | Huber Martin H. Jr.President, CEO | SSale | −2.01K | $7.31 | −$14.7K | −17.4%9.57K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Huber Martin H. Jr.President, CEO | SSale | −4.51K | $0.58 | −$2.62K | −3.5%122.9K after | 10b5-1 |
| Sep 13, 2024 (view filing) | Sep 12 | 1 day | Huber Martin H. Jr.President, CEO | SSale | −50.4K | $1.76 | −$88.7K | −30.2%116.3K after | 10b5-1 |
SNDX Syndax Pharmaceuticals Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2025 (view filing) | May 19 | Same day | Huber Martin H. Jr.Director | PPurchase | +5.00K | $8.99 | +$45.0K | +6.8%79.0K after |